• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»oncology diagnostics (Page 2)

Guardant Health brings Shield multi-cancer detection test to Asia through Manulife insurer deal

By Pallavi Madhiraju on March 17, 2026   Medical Devices & Diagnostics  

Guardant Health brings Shield multi-cancer detection test to Asia through Manulife insurer deal

Guardant Health partners with Manulife to launch its Shield MCD blood test in Hong Kong, Singapore and the Philippines. Analysis of what this means for oncology.

Pillar Biosciences launches rapid AML sequencing panel while Creatv Bio liquid biopsy enters colorectal cancer trial biomarker role

By Pallavi Madhiraju on March 8, 2026   Medical Devices & Diagnostics  

Pillar Biosciences launches rapid AML sequencing panel while Creatv Bio liquid biopsy enters colorectal cancer trial biomarker role

Pillar Biosciences launches rapid AML sequencing panel as Creatv Bio liquid biopsy enters colorectal cancer trial. Explore what these tools mean for oncology research.

How Creatv Bio’s LifeTracDx may change immune biomarker tracking in colorectal cancer studies

By Pallavi Madhiraju on March 8, 2026   Medical Devices & Diagnostics  

How Creatv Bio’s LifeTracDx may change immune biomarker tracking in colorectal cancer studies

Creatv Bio’s LifeTracDx joins CytoDyn’s Phase 2 colorectal cancer trial as a liquid biopsy biomarker tool. Discover what this means for oncology diagnostics.

Can ClearNote Health’s Avantect test finally close the early detection gap in pancreatic cancer

By Pallavi Madhiraju on February 26, 2026   Medical Devices & Diagnostics  

Can ClearNote Health’s Avantect test finally close the early detection gap in pancreatic cancer

ClearNote Health’s updated Avantect test improves pancreatic cancer detection in high-risk patients. Find out what this changes for early screening strategies.

Why Project Santa Fe Foundation and Virchow Medical are testing a proactive future for oncology diagnostics

By Pallavi Madhiraju on February 20, 2026   Medical Devices & Diagnostics  

Why Project Santa Fe Foundation and Virchow Medical are testing a proactive future for oncology diagnostics

Project Santa Fe Foundation and Virchow Medical are redefining oncology diagnostics through proactive analytics. Find out what this changes for labs and clinicians.

Why 10x Genomics is betting on CLIA lab certification to advance spatial diagnostics in oncology

By Pallavi Madhiraju on January 12, 2026   Medical Devices & Diagnostics  

Why 10x Genomics is betting on CLIA lab certification to advance spatial diagnostics in oncology

Find out how 10x Genomics and Dana-Farber aim to transform cancer diagnostics using spatial biology and single cell profiling for real-world clinical decisions.

Can personalized ctDNA finally solve the risk stratification gap in therapy-resistant early breast cancer?

By Pallavi Madhiraju on December 16, 2025   Medical Devices & Diagnostics  

Can personalized ctDNA finally solve the risk stratification gap in therapy-resistant early breast cancer?

New I-SPY 2 data suggest personalized ctDNA could transform risk stratification in therapy-resistant early breast cancer. Read the full analysis.

How GE HealthCare and Tribun Health are rethinking oncology workflows

By Venkatesh B on December 10, 2025   Medical Devices & Diagnostics  

How GE HealthCare and Tribun Health are rethinking oncology workflows

GE HealthCare and Tribun Health join forces to unify cancer diagnostics at Sant’ Andrea Hospital. See how digital pathology is reshaping oncology workflows.

« Previous 1 2

Recent Posts

  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
  • Why Tempus AI’s Lens upgrade matters for precision oncology drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes